- body fat
- lipid metabolism
Lactobacillus amylovorous CP1563
Lactobacillus amylovorous CP1563
A lactic acid bacterial strain selected from the Asahi Group’s extensive library of proprietary lactic acid bacteria for its high potential to promote fat loss. A proprietary concept involving the crushing of lactic acid bacteria to enable more efficient bodily absorption of the bacterial components has been shown to improve lipid metabolism.*
*Patent Nos. 5801802, 5690435 and 5690416 (as of December 2016)
Research background
The Asahi Group’s research on lactic acid bacteria and fermented milk can be traced back to Calpis, a company that produced and released Japan’s first lactic acid bacteria beverage in 1919. Tests done on mice in the 1970s as part of a collaborative research project between Calpis (then still an independent company) and Riken found that longevity was promoted by a proprietary formulation of fermented milk made from lactic acid bacteria and yeast. This work inspired the Group to seek out new strains of functional lactic acid bacteria that promote healthy life extension, and work on creating advanced technologies for using lactic acid bacteria.
Major research findings
- Found to reduce body fat
- Found to improve levels of LDL cholesterol, blood sugar and uric acid
Creating a society of health and abundance
A close link has been found between obesity and a number of lifestyle diseases such as diabetes, high cholesterol and high blood pressure. Eating a well-balanced diet and getting moderate exercise on a regular basis is a key first step for avoiding obesity. But these habits should be supplemented by taking full advantage of the benefits provided by lactic acid bacteria, a promising weapon in the fight against obesity that can prevent lifestyle diseases while promoting vitality, health and longevity.
Research information on Lactobacillus amylovorous CP1563
-
Paper
Fragmented lactic acid bacterial cells activate peroxisome proliferator-activated receptors and ameliorate dyslipidemia in obese mice.